<DOC>
	<DOCNO>NCT00001249</DOCNO>
	<brief_summary>The study purpose evaluate clinical response multidose administration anti-Tac monoclonal antibody conjugate 10 mCi 90Y patient Tac-expressing adult T-cell leukemia ( ATL ) .</brief_summary>
	<brief_title>Treatment Tac-Expressing Cutaneous T-Cell Lymphoma ( CTCL ) Adult T-Cell Leukemia ( ATL ) With Yttrium-90 Radiolabeled Anti-Tac</brief_title>
	<detailed_description>The study purpose evaluate clinical response multidose administration anti-Tac monoclonal antibody conjugate 10 mCi 90Y patient Tac-expressing adult T-cell leukemia ( ATL ) . This study represent extension phase I trial ( Clinical Project # 90-C-0043 , FDA IND # 3469 ) permit administration 5 mCi , 10 mCi , 15mCi 90Y-anti-Tac patient ATL . We propose administer 90Y-anti-Tac ( 10 mCi dos ) patient Tac-expressing ATL 18 year age fill patient eligibility criterion .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adult Tcell leukemia/lymphoma ( ATL ) cutaneous Tcell lymphoma ( CTCL ) . Reactivity least 10 % peripheral blood , lymph node , dermal malignant cell antiTac determine immunofluorescent stain soluble IL2 receptor level great 1,500 U require . All stage Tacexpressing Tcell leukemia lymphoma eligible except Stage I CTCL . All form ATL eligible , include `` smolder '' type well aggressive disease . No symptomatic CNS disease tropical spastic paraparesis . Asymptomatic CNS disease demonstrable malignant cell CSF allow ( patient receive CNS therapy , e.g. , intrathecal methotrexate and/or CNS irradiation , appropriate ) . PRIOR/CONCURRENT THERAPY : Biologic Therapy : Not specify . Chemotherapy : CTCL must fail initial chemotherapy . ATL may may prior chemotherapy . At least 4 week since prior cytotoxic chemotherapy . Endocrine Therapy : Not specify . Radiotherapy : At least 4 week since prior radiotherapy . Surgery : Not specify . PATIENT CHARACTERISTICS : Age : 18 . Performance status : Not specify . Life expectancy : Greater 1 month . Hematopoietic : WBC least 3,000 , Platelets least 75,000 . Hepatic : Not specify . Renal : Not specify . Other : No pregnant woman . Negative pregnancy test require fertile woman .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1999</verification_date>
	<keyword>Interleukin-2 Receptor</keyword>
</DOC>